Edgewise Net Receivables from 2010 to 2024

EWTX Stock  USD 31.98  0.22  0.68%   
Edgewise Therapeutics Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2024. During the period from 2010 to 2024, Edgewise Therapeutics Net Receivables regression line of annual values had r-squared of  0.46 and arithmetic mean of  491,500. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
225.9 K
Current Value
319.6 K
Quarterly Volatility
118.4 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edgewise Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edgewise Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 14.9 M, Interest Income of 14.9 M or Depreciation And Amortization of 1.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.3. Edgewise financial statements analysis is a perfect complement when working with Edgewise Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Edgewise Therapeutics Correlation against competitors.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.

Latest Edgewise Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Edgewise Therapeutics over the last few years. It is Edgewise Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edgewise Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Edgewise Net Receivables Regression Statistics

Arithmetic Mean491,500
Geometric Mean473,047
Coefficient Of Variation24.09
Mean Deviation90,400
Median548,000
Standard Deviation118,394
Sample Variance14B
Range322.1K
R-Value(0.68)
Mean Square Error8.2B
R-Squared0.46
Significance0.01
Slope(17,916)
Total Sum of Squares196.2B

Edgewise Net Receivables History

2024319.6 K
2023225.9 K
2022251 K

About Edgewise Therapeutics Financial Statements

Edgewise Therapeutics investors use historical fundamental indicators, such as Edgewise Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edgewise Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables225.9 K319.6 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.